Literature DB >> 22425791

Human monoclonal antibodies generated following vaccination with AVA provide neutralization by blocking furin cleavage but not by preventing oligomerization.

Kenneth Smith1, Sherry R Crowe, Lori Garman, Carla J Guthridge, Jennifer J Muther, Emily McKee, Nai-Ying Zheng, A Darise Farris, Joel M Guthridge, Patrick C Wilson, Judith A James.   

Abstract

In order to identify the combination of antibody-mediated mechanisms of neutralization that result from vaccination with anthrax vaccine adsorbed (AVA), we isolated antibody secreting cells from a single donor seven days after booster vaccination with AVA and generated nine fully human monoclonal antibodies (hmAb) with high specificity for protective antigen (PA). Two of the antibodies were able to neutralize lethal toxin in vitro at low concentrations (IC(50): p6C01, 0.12 μg/ml and p6F01, 0.45 μg/ml). Passive transfer of either of these hmAbs to A/J mice prior to challenge with lethal toxin conferred 80-90% protection. We demonstrate that hmAb p6C01 is neutralizing by preventing furin cleavage of PA in a dose-dependent manner, but the mechanism of p6F01 is unclear. Three additional antibodies were found to bind to domain 3 of PA and prevent oligomerization, although they did not confer significant protection in vivo and showed a significant prozone-like effect in vitro. These fully human antibodies provide insight into the neutralizing response to AVA for future subunit vaccine and passive immunotherapeutic cocktail design.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22425791      PMCID: PMC3367042          DOI: 10.1016/j.vaccine.2012.03.002

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  39 in total

1.  Mapping the lethal factor and edema factor binding sites on oligomeric anthrax protective antigen.

Authors:  Kristina Cunningham; D Borden Lacy; Jeremy Mogridge; R John Collier
Journal:  Proc Natl Acad Sci U S A       Date:  2002-05-07       Impact factor: 11.205

Review 2.  Anthrax toxin: receptor binding, internalization, pore formation, and translocation.

Authors:  John A T Young; R John Collier
Journal:  Annu Rev Biochem       Date:  2007       Impact factor: 23.643

3.  Human monoclonal antibodies that neutralize anthrax toxin by inhibiting heptamer assembly.

Authors:  Fei Wang; Paul Ruther; Ivy Jiang; Ritsuko Sawada-Hirai; Shu Man Sun; Rebecca Nedellec; Phillip R Morrow; Angray S Kang
Journal:  Hum Antibodies       Date:  2004

4.  Effects of a reduced dose schedule and intramuscular administration of anthrax vaccine adsorbed on immunogenicity and safety at 7 months: a randomized trial.

Authors:  Nina Marano; Brian D Plikaytis; Stacey W Martin; Charles Rose; Vera A Semenova; Sandra K Martin; Alison E Freeman; Han Li; Mark J Mulligan; Scott D Parker; Janiine Babcock; Wendy Keitel; Hana El Sahly; Gregory A Poland; Robert M Jacobson; Harry L Keyserling; Stephen D Soroka; Sarah P Fox; John L Stamper; Michael M McNeil; Bradley A Perkins; Nancy Messonnier; Conrad P Quinn
Journal:  JAMA       Date:  2008-10-01       Impact factor: 56.272

5.  Mass value assignment of total and subclass immunoglobulin G in a human standard anthrax reference serum.

Authors:  V A Semenova; E Steward-Clark; K L Stamey; T H Taylor; D S Schmidt; S K Martin; N Marano; C P Quinn
Journal:  Clin Diagn Lab Immunol       Date:  2004-09

6.  Novel chimpanzee/human monoclonal antibodies that neutralize anthrax lethal factor, and evidence for possible synergy with anti-protective antigen antibody.

Authors:  Zhaochun Chen; Mahtab Moayeri; Devorah Crown; Suzanne Emerson; Inna Gorshkova; Peter Schuck; Stephen H Leppla; Robert H Purcell
Journal:  Infect Immun       Date:  2009-06-15       Impact factor: 3.441

7.  Efficient neutralization of anthrax toxin by chimpanzee monoclonal antibodies against protective antigen.

Authors:  Zhaochun Chen; Mahtab Moayeri; Yi-Hua Zhou; Stephen Leppla; Suzanne Emerson; Andrew Sebrell; Fujuan Yu; Juraj Svitel; Peter Schuck; Marisa St Claire; Robert Purcell
Journal:  J Infect Dis       Date:  2006-02-02       Impact factor: 5.226

8.  Production and characterization of neutralizing monoclonal antibodies that recognize an epitope in domain 2 of Bacillus anthracis protective antigen.

Authors:  Michael J Gubbins; Jody D Berry; Cindi R Corbett; Jeremy Mogridge; Xin Y Yuan; Lisa Schmidt; Brigitte Nicolas; Amin Kabani; Raymond S Tsang
Journal:  FEMS Immunol Med Microbiol       Date:  2006-08

9.  Isolation and chimerization of a highly neutralizing antibody conferring passive protection against lethal Bacillus anthracis infection.

Authors:  Ronit Rosenfeld; Hadar Marcus; Einat Ben-Arie; Bat-El Lachmi; Adva Mechaly; Shaul Reuveny; Orit Gat; Ohad Mazor; Arie Ordentlich
Journal:  PLoS One       Date:  2009-07-24       Impact factor: 3.240

10.  Human anti-anthrax protective antigen neutralizing monoclonal antibodies derived from donors vaccinated with anthrax vaccine adsorbed.

Authors:  Ritsuko Sawada-Hirai; Ivy Jiang; Fei Wang; Shu Man Sun; Rebecca Nedellec; Paul Ruther; Alejandro Alvarez; Diane Millis; Phillip R Morrow; Angray S Kang
Journal:  J Immune Based Ther Vaccines       Date:  2004-05-12
View more
  16 in total

1.  A fully human monoclonal antibody with novel binding epitope and excellent neutralizing activity to multiple human IFN-α subtypes: A candidate therapy for systemic lupus erythematosus.

Authors:  Peng Du; Lei Xu; Weiyi Qiu; Dadi Zeng; Junjie Yue; Shuang Wang; Peitang Huang; Zhiwei Sun
Journal:  MAbs       Date:  2015       Impact factor: 5.857

2.  Generation and Characterization of Human Monoclonal Antibodies Targeting Anthrax Protective Antigen following Vaccination with a Recombinant Protective Antigen Vaccine.

Authors:  Xiangyang Chi; Jianmin Li; Weicen Liu; Xiaolin Wang; Kexin Yin; Ju Liu; Xiaodong Zai; Liangliang Li; Xiaohong Song; Jun Zhang; Xiaopeng Zhang; Ying Yin; Ling Fu; Junjie Xu; Changming Yu; Wei Chen
Journal:  Clin Vaccine Immunol       Date:  2015-03-18

Review 3.  An overview of investigational toxin-directed therapies for the adjunctive management of Bacillus anthracis infection and sepsis.

Authors:  Lernik Ohanjanian; Kenneth E Remy; Yan Li; Xizhong Cui; Peter Q Eichacker
Journal:  Expert Opin Investig Drugs       Date:  2015-04-28       Impact factor: 6.206

4.  Stochastic humoral immunity to Bacillus anthracis protective antigen: identification of anti-peptide IgG correlating with seroconversion to Lethal Toxin neutralization.

Authors:  Eric K Dumas; Melissa L Nguyen; Philip M Cox; Heidi Rodgers; Joanne L Peterson; Judith A James; A Darise Farris
Journal:  Vaccine       Date:  2013-02-13       Impact factor: 3.641

5.  Antigen nature and complexity influence human antibody light chain usage and specificity.

Authors:  Kenneth Smith; Hemangi Shah; Jennifer J Muther; Angie L Duke; Kathleen Haley; Judith A James
Journal:  Vaccine       Date:  2016-04-23       Impact factor: 3.641

6.  Characterization of the native form of anthrax lethal factor for use in the toxin neutralization assay.

Authors:  Hang Lu; Jason Catania; Katalin Baranji; Jie Feng; Mili Gu; Janet Lathey; Diane Sweeny; Hannah Sanford; Kavita Sapru; Terry Patamawenu; June-Home Chen; Alan Ng; Zenbework Fesseha; Stefanie Kluepfel-Stahl; Jacob Minang; David Alleva
Journal:  Clin Vaccine Immunol       Date:  2013-05-01

7.  Fully human monoclonal antibodies from antibody secreting cells after vaccination with Pneumovax®23 are serotype specific and facilitate opsonophagocytosis.

Authors:  Kenneth Smith; Jennifer J Muther; Angie L Duke; Emily McKee; Nai-Ying Zheng; Patrick C Wilson; Judith A James
Journal:  Immunobiology       Date:  2012-09-03       Impact factor: 3.144

Review 8.  Anthrax lethal toxin and the induction of CD4 T cell immunity.

Authors:  Stephanie Ascough; Rebecca J Ingram; Daniel M Altmann
Journal:  Toxins (Basel)       Date:  2012-10-19       Impact factor: 4.546

Review 9.  Monoclonal antibodies and toxins--a perspective on function and isotype.

Authors:  Siu-Kei Chow; Arturo Casadevall
Journal:  Toxins (Basel)       Date:  2012-06-11       Impact factor: 4.546

10.  Insufficient Anthrax Lethal Toxin Neutralization Is Associated with Antibody Subclass and Domain Specificity in the Plasma of Anthrax-Vaccinated Individuals.

Authors:  Kenneth Smith; Lori Garman; Kathleen Norris; Jennifer Muther; Angie Duke; Renata J M Engler; Michael R Nelson; Limone C Collins; Christina Spooner; Carla Guthridge; Judith A James
Journal:  Microorganisms       Date:  2021-06-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.